BioSpace News Archive

KMZ Holdings LLC (https://www.kmzholdings.net), a cutting-edge medical diagnostic company owning a patented, proprietary cloud-based evolutionary tool for the medical field, proudly announces a stunning application of subatomic Femto Technology principles to its new product Femto Water.

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending September 30, 2020.

The Volunteers of America Classic – the only LPGA event in Texas - announces the speaker lineup for the Women’s Leadership Summit presented by Versant Health to be hosted virtually December 1, 2020

Kaiser Permanente announced that Andrew Bindman, MD, has joined the organization as executive vice president and chief medical officer.

Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, , at 4:30pm EST, will provide an update and overview of its clinical development pipeline / activities and its financial results for the third quarter ended September 30, 2020.

ICU Medical, Inc., a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, announced financial results for the quarter ended September 30, 2020.

Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on November 5, 2020

Strengthened Formulary Access for Xtampza® ER, Including Exclusive National Medicare Part D Win

iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced that management will participate in the upcoming virtual investor conferences in November:

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, announced that Otis Brawley, M.D., has been appointed to PDS Biotech’s Board of Directors.